Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  New England Journal of Medicine

• Publication date

  1994-10-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00019616-199503000-00021PMID 7935635
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.

  1994cited by this paper
• A ticket to ride: peptide radiopharmaceuticals.

  1993cited by this paper
• Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

  1993cited by this paper
• Murine mucosal T cells have VIP receptors functionally distinct from those on intestinal epithelial cells.

  1992cited by this paper
• Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.

  1992cited by this paper
• Cloning and expression of the human vasoactive intestinal peptide receptor.

  1991cited by this paper
• Indium-111-labeled low-density lipoprotein binds with higher affinity to the human liver as compared to iodine-123-low-density-labeled lipoprotein.

  1991cited by this paper
• Somatostatin-receptor imaging in the localization of endocrine tumors.

  1990cited by this paper
• Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin.

  1989cited by this paper
• Solubilization of the active vasoactive intestinal peptide receptor from human colonic adenocarcinoma cells.

  1988cited by this paper
• Molecular characteristics and evidence for internalization of vasoactive-intestinal-peptide (VIP) receptors in the tumoral rat-pancreatic acinar cell line AR 4-2 J.

  1988cited by this paper
• Characterization of receptors for vasoactive intestinal peptide solubilized from the lung.

  1987cited by this paper
• The human vasoactive intestinal peptide receptor: molecular identification by covalent cross-linking in colonic epithelium.

  1985cited by this paper
• Vasoactive intestinal peptide and neuropeptide modulation of the immune response.

  1985cited by this paper
• In vitro alteration of receptors for vasoactive intestinal peptide changes the in vivo localization of mouse T cells

  1984cited by this paper
• Elevated plasma and tissue levels of vasoactive intestinal polypeptide in the watery-diarrhea syndrome due to pancreatic, bronchogenic and other tumors.

  1975cited by this paper
• Vasoactive intestinal peptide stimulation of adenylate cyclase and active electrolyte secretion in intestinal mucosa.

  1974cited by this paper
• Vasoactive intestinal peptide and watery-diarrhoea syndrome.

  1973cited by this paper
• VASOACTIVE INTESTINAL PEPTIDE AND WATERY-DIARRHŒA SYNDROME

  1973cited by this paper
• Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia.

  1958cited by this paper

• Reprogramming neural-tumor crosstalk: emerging therapeutic dimensions and targeting strategies

  2025cites this paper
• Neuropeptides or their receptors in pathogenesis of lung diseases and therapeutic potentials.

  2024cites this paper
• Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.

  2023cites this paper
• The role of vasoactive intestinal peptide in pulmonary diseases.

  2023cites this paper
• Signal Transduction by VIP and PACAP Receptors

  2022cites this paper
• A Prognostic Model Using Immune-Related Genes for Colorectal Cancer

  2022cites this paper
• Development of a prognostic index and screening of potential biomarkers based on immunogenomic landscape analysis of colorectal cancer

  2020cites this paper
• Study the 99m Tc-labeling conditions of HYNIC-conjugated peptides from a new perspective: Introduction to the term radio-stoichiometry.

  2020cites this paper
• Peptide receptors as cancer drug targets

  2019cites this paper
• Biomedical applications of radioiodinated peptides.

  2019cites this paper
• Stress and Immunity

  2019cites this paper
• Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer

  2017cites this paper
• Cross sectional and nuclear medicine imaging of pancreatic insulinomas

  2017cites this paper
• Peptides as Orthopedic Biomaterials

  2017cites this paper
• Molecular imaging probes derived from natural peptides.

  2016cites this paper
• A review of the ligands and related targeting strategies for active targeting of paclitaxel to tumours

  2016cites this paper
• Neuroendocrine Differentiation of a Primary BRAF Mutant Colon Cancer in a Patient With a History of Hairy Cell Leukemia.

  2016cites this paper
• Лапароскопическая хирургия толстой и прямой кишки

  2016cites this paper
• Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer

  2016cites this paper
• Basis of Radiopharmaceutical Localization

  2015cites this paper
• Hormone and Receptor Candidates for Target and Biotherapy of Neuroendocrine Tumors.

  2015cites this paper
• VPAC2 receptor expression in human normal and neoplastic tissues: evaluation of the novel MAB SP235

  2015cites this paper
• Neuropeptides as lung cancer growth factors.

  2015cites this paper
• Vasoactive Intestinal Peptide (VIP) Nanoparticles for Diagnostics and for Controlled and Targeted Drug Delivery.

  2015cites this paper
• Molecular imaging of the pulmonary circulation in health and disease

  2014cites this paper
• Single-photon emission computed tomography tracers for predicting and monitoring cancer therapy.

  2014cites this paper
• Vasoactive intestinal peptide receptor-based imaging and treatment of tumors (Review).

  2014influential citation
• Basis of Radiopharmaceutical Localization

  2014cites this paper
• Radiolabeled biomolecules for specific imaging of cancers of the breast, prostate and lungs

  2014cites this paper
• GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs).

  2014cites this paper
• GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs).

  2014cites this paper
• F-18 Labeled Vasoactive Intestinal Peptide Analogue in the PET Imaging of Colon Carcinoma in Nude Mice

  2013cites this paper
• Antihistaminergics and inverse agonism: potential therapeutic applications.

  2013cites this paper
• Design and evaluation of novel radiolabelled VIP derivatives for tumour targeting.

  2013cites this paper
• Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent

  2012cites this paper
• Criteria for the Design and Biological Characterization of Radiolabeled Peptide-Based Pharmaceuticals

  2012cites this paper
• Peptide-receptor ligands and multivalent approach.

  2012cites this paper
• VIP-targeted cytotoxic nanomedicine for breast cancer

  2012cites this paper
• Functional and Morphological Imaging of the Endocrine System

  2012cites this paper
• Identification and optimization of small molecule antagonists of vasoactive intestinal peptide receptor-1 (VIPR1).

  2012cites this paper
• Radiolabeled Peptides in Oncology

  2012cites this paper
• Peptide‐labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells

  2011cites this paper
• Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals.

  2010cites this paper
• Clinical Detection and Treatment of Pancreatic Neuroendocrine Tumors

  2010cites this paper
• Response of Recurrent High-Grade Glioma to Treatment with 90Y-DOTATOC

  2010cites this paper
• (99m)Tc-radiolabelled peptides for tumour imaging: present and future.

  2010cites this paper
• Genetic and Molecular Approaches to Imaging Breast Cancer

  2010cites this paper
• Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis.

  2010cites this paper
• Targeted radionuclide therapy of cancer

  2009cites this paper
• Colonic carcinoid tumors: a clinicopathologic study of 23 patients from a single institution.

  2009cites this paper
• Imaging in targeted delivery of therapy to cancer

  2009cites this paper
• Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours.

  2009cites this paper
• Clinical radionuclide therapy

  2008cites this paper
• Radiometal targeted tumor diagnosis and therapy with peptide hormones.

  2008cites this paper
• Endoradiotherapy with peptides - status and future development.

  2008cites this paper
• Receptor PET/CT imaging of neuroendocrine tumors.

  2008cites this paper
• PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and Metabolism.

  2008cites this paper
• True radiotracers: are we approaching theoretical specific activity with Tc-99m and I-123?

  2008cites this paper
• VPAC receptors as target for anti-cancer drug delivery

  2008influential citation
• Preclinical evaluation of somatostatin analogs bearing two macrocyclic chelators for high specific activity labeling with radiometals

  2007cites this paper
• Invited commentary to: "Current status and future directions of radioimmunotherapy"

  2007cites this paper
• Development and application of peptide-based radiopharmaceuticals.

  2007cites this paper
• Endokrine Tumoren des gastroenteropankreatischen Systems

  2007cites this paper
• Identification of neuropeptide Y cleavage products in human blood to improve metabolic stability.

  2007cites this paper
• Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer.

  2007cites this paper
• Peptides radiolabeled with Re-186/188 and Tc-99m as potential diagnostic and therapeutic agents

  2007cites this paper
• PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and Metabolism.

  2007cites this paper
• Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation.

  2007cites this paper
• Radiosynthesis of 18F-(R8,15,21, L17)-vasoactive intestinal peptide and preliminary evaluation in mice bearing C26 colorectal tumours

  2007cites this paper
• 99mTc(CO)3-VIP analogues: preparation and evaluation as tumor imaging agent.

  2007cites this paper
• Mechanisms of inverse agonism at histamine H2 receptors – potential benefits and concerns

  2006cites this paper
• Radiopharmaceuticals: Recent Developments and Trends

  2006cites this paper
• Pathophysiology and Mechanisms of Radiopharmaceutical Localization

  2006cites this paper
• Entwicklung neuer rezeptorgesteuerter Radiopharmazeutika für die Therapie von malignen Hirntumoren und medullären Schilddrüsenkarzinomen

  2006cites this paper
• Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours.

  2006cites this paper
• VIP and PACAP as Autocrine Growth Factors in Breast and Lung Cancer

  2006cites this paper
• Imaging of neuroendocrine tumors.

  2006cites this paper
• Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma

  2006cites this paper
• Vasoactive Intestinal Peptide Receptor Agonist : Functional Studies

  2006cites this paper
• In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers.

  2006cites this paper
• Peptide hormones and lung cancer.

  2006cites this paper
• Radiolabeling and in vitro and in vivo Characterization of [18F]FB‐[R8,15,21, L17]‐VIP as a PET Imaging Agent for Tumor Overexpressed VIP Receptors

  2006cites this paper
• Molecular Imaging Probes for PET and SPECT

  2005cites this paper
• Einfluss molekularbiologischer Verfahren auf nuklearmedizinische Methoden

  2005cites this paper
• The diagnostic utility of somatostatin receptor scintigraphy in oncology

  2005cites this paper
• Human VIP-alpha: an emerging biologic response modifier to treat primary pulmonary hypertension.

  2005cites this paper
• Radiometallation of receptor-specific peptides for diagnosis and treatment of human cancer.

  2005cites this paper
• PROPERTIES AND BIOTECHNOLOGICAL USE

  2005cites this paper
• The role of the hypothalamo-pituitary axis in headache.

  2005cites this paper
• Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?

  2005cites this paper
• Neue, radioaktiv markierte und Magnet-Resonanz-aktive Somatostatinanaloga zur besseren Diagnose und zielgerichteten radionuklidtherapie von neuroendokrinen Tumoren

  2005cites this paper
• Radiolabeled peptides in oncology: role in diagnosis and treatment.

  2005cites this paper
• Human VIP-α: an emerging biologic response modifier to treat primary pulmonary hypertension

  2005cites this paper
• Selenocysteine in proteins-properties and biotechnological use.

  2005cites this paper
• The radionuclide molecular imaging and therapy of neuroendocrine tumors.

  2005cites this paper
• N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo.

  2005cites this paper
• Novel 99mTc radiolabeled quinazolinone derivative [Qn-In]: synthesis, evaluation and biodistribution studies in mice and rabbit.

  2004cites this paper
• In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging.

  2004cites this paper
• PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog.

  2004cites this paper
• 177Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy.

  2004cites this paper